Abstract
T1 mapping is now a clinically feasible method, providing pixel-wise quantification of the cardiac structure’s T1 values. Beyond focal lesions, well depicted by late gadolinium enhancement sequences, it has become possible to discriminate diffuse myocardial alterations, previously not assessable by noninvasive means. The strength of this method includes the high reproducibility and immediate clinical applicability, even without the use of contrast media injection (native or pre-contrast T1). The two most important determinants of native T1 augmentation are (1) edema related to tissue water increase (recent infarction or inflammation) and (2) interstitial space increase related to fibrosis (infarction scar, cardiomyopathy) or to amyloidosis. Conversely, lipid (Anderson–Fabry) or iron overload diseases are responsible for T1 reduction. In this pictorial review, the main features provided by native T1 mapping are discussed and illustrated, with a special focus on the awaited clinical purpose of this unique, promising new method.
Keywords: cardiac magnetic resonance, T1 mapping, edema, myocardial infarction, fibrosis, cardiomyopathy
Introduction
The ability to discriminate between T1 and T2 tissue contrast is a unique strength of magnetic resonance imaging. In the past years, new pulse sequences, achievable through breath-hold, were developed, aimed at providing clinically feasible parametric images in which each pixel directly corresponds to the T1 or T2 value of cardiac tissues.1 Regarding T1 mapping, the MOLLI sequence described in 2004 by Messroghli et al.2 and the faster ShMOLLI sequence3 developed by the group of Oxford constitute a real breakthrough, offering robust, fast, and practical quantification of T1 tissue values, immediately available on the scanner console, circumventing the influence of windowing, without a need for manual post-processing. Such a change from visualization to quantification has been described as a true “revolution” of cardiac magnetic resonance (CMR),4 reducing the subjectivity encountered in traditional nonquantitative techniques and providing the ability to differentiate between “normal” and “affected” myocardium. T1 mapping may be performed before (pre-contrast or native T1, reflecting composite water signal from extracellular space and myocytes) but also after contrast media injection (allowing determination of extracellular volume fraction). In this review, we thought to summarize the most salient results obtained with native T1 mapping and to illustrate the potential clinical utility of this technique through a series of cases. Since pre-contrast T1 will only be considered here, the expression “T1” will be used to mean native, pre-contrast T1 in the following paragraphs.
Normal native myocardial T1 values measured with MOLLI at 1.5 T lie between 900 and 1100 ms, but depend on several technical and physiological parameters. In particular, from 1.5 to 3.0 Tesla field, T1 augmentation was reported to be between 14% and 28% greater. In this article, all presented images were obtained with the basic MOLLI sequence of the Siemens Tx-mapping WIP780, on a 1.5 T Aera scanner. Reported T1 values result from myocardial region of interest (ROI) tracing (being careful to exclude the blood pool as well as the epicardial fat). For the purpose of comparison with published data, mean normal myocardial T1 value determined in our center was 1032 ± 39 ms.
The longitudinal relaxation time T1 is increased in (1) edema resulting from myocardial injury or inflammation, cellular edema, myocyte necrosis and (2) in the case of extracellular space expansion induced by amyloidosis infiltration or by fibrosis, either focal (replacement fibrosis, infarct scar) or diffuse (interstitial fibrosis increased in hypertrophic cardiomyopathy [HCM] and dilated cardiomyopathy [DCM]). Thus, T1 increase is ubiquitous and the use of other complementary imaging sequences such as T2-STIR and late gadolinium enhancement sequences (LGE) is mandatory (summarized in Table 1), as well as interpretation within the clinical context. On the other hand, main causes of T1 reduction include fatty infiltration (lipomatous metaplasia), intracellular sphingolipids overload (Anderson–Fabry), and iron overload diseases. The order of magnitude for the most important T1 alterations recently published is listed in Table 2.
Table 1.
DISEASE | T1 | T2 | LGE | |
---|---|---|---|---|
EDEMA | Aborted MI, Tako-Tsubo | Increased | Increased | None |
Acute MI, or myocarditis | Increased | Increased | Present | |
FIBROSIS | Focal (replacement) or diffuse (interstitial) | Increased | Normal | Detectable if focal |
Note: T1 is increased in several categories of cardiac lesions, which may not be discriminated unless T2 and LGE imaging are used as complementary tools (similarly with histology, which relies on various stains to characterize tissue pathology).
Table 2.
DISEASE | FOCAL ALTERATION | DIFFUSE ALTERATION | REFERENCE | NOTA | |
---|---|---|---|---|---|
EDEMA | Acute MI | +18% vs remote +24% vs remote +5 to 9% vs remote ≈+24% vs remote |
+3% vs healthy, NS (increased vs healthy) ≈+20% vs healthy |
Messroghli et al.9 Ugander8 Dall’Armellina11 Dall’Armellina22 |
MOLLI 1.5 T, n = 24 MOLLI 1,5 T (9 dogs) ShMOLLI 3 T, n = 41 ShMOLLI 3 T, n = 5 |
Acute myocarditis | +12% vs healthy | +7% vs healthy +9% vs controls |
Ferreira13,15 Luetkens14 |
ShMOLLI, 1.5 T, n = 60 MOLLI 3 T, n = 24 |
|
Tako-Tsubo | +18% vs healthy | +9% vs healthy | Ferreira7 | ShMOLLI 1.5 T, n = 21 | |
FIBROSIS | Chronic MI, scar | +7% vs remote +20% vs remote |
Messroghli9 Okur25 |
MOLLI 1.5 T, n = 24 MOLLI 3 T, n = 26 |
|
DCM or Heart failure | +16% +4% +2% NS |
Puntmann29 Dass30 Su28 |
MOLLI 3 T, n = 27 ShMOLLI 3 T, n = 19 MOLLI 3 T, n = 102 |
||
HCM | +17% +3% |
Puntmann29 Dass30 |
MOLLI 3 T, n = 25 ShMOLLI 3 T, n = 28 |
||
Pressure overload | +7% Mild increase (graph) +3.4% |
Bull26 Sado39 Lee27 |
ShM 1.5 T, 24 AS. ShM 1.5 T,41HT 21 AS MOLLI 3 T, 80 AS |
||
Lupus (subclinical) Systemic sclerosis |
+9% +5% |
Puntmann32 Ntusi33 |
MOLLI 3 T, n = 33 ShMOLLI, 1.5 T, n = 19 |
||
OTHER | Amyloidosis | +19% vs healthy +13% ATTR, +17% AL |
Karamitsos35 Fontana36 |
ShMOLLI 1.5 T, n = 53 ShMOLLI 1,5 T n = 85,79 |
|
Anderson–Fabry | −9% vs healthy | Sado38 | ShMOLLI 1.5 T, n = 44 | ||
Iron deposition | −14% vs healthy | Sado39,40 | ShMOLLI 1.5 T, n = 88 |
Notes: Focal lesions are compared to either remote myocardium (same patient) or healthy myocardium (control series). Diffuse lesions are compared to healthy myocardium (control series). Magnetic field: 1.5 T or 3 T. Sequence: MOLLI or ShMOLLI.
Abbreviations: n, number of patients; MI, myocardial infarction; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; AS, aortic stenosis; HT, hypertension; NS, not significant.
Edema
Area at risk and salvaged myocardium after acute infarction
In 1983, Higgins et al.5 demonstrated in dogs that the percentage of water content in an acute myocardial infarction (MI) is approximately 4% greater than that in normal regions and that T1 and T2 values in the area of infarction are greater than those of normal myocardium. This focal T1 increase in water content is related to cellular destruction (infarct core) and to surrounding interstitial edema and may last up to one or two months after acute infarction.6 In the case of edema, Ferreira et al demonstrated that T1 mapping was significantly more sensitive than STIR-T2,7 and in the setting of experimental acute infarction, Ugander et al showed that both T1 mapping and T2 mapping were similarly sensitive to tissue edema and are closely correlated with the area at risk as assessed by microsphere in animal study.8 As it can be seen in Figure 1, in the area of acute MI identified by LGE, the T1 increase is in the range ≈+20% vs remote myocardium (see Table 2). Edema-related T1 elevation over several standard deviation (SD) above normal values allows for the identification of acute MI with sensitivity and specificity >90%.9,10 LGE appears less extensive than increased T1 area but is more specific to myocardial necrosis. The difference between the area at risk (T1 increase) and necrosis (LGE, with a smaller size) corresponds to the salvaged myocardium. In the clinical study of Dal’Armellina et al.11, the diagnostic performance of T1 mapping was similar to that of T2-prep sequence (similar extension of salvaged myocardium). Moreover, T1 mapping seems to be more robust (better reproducibility) than T2-weighted imaging, and increased T1 values have a prognostic significance (weaker segmental function improvement at 6M). The surface area of abnormal myocardium may be visually estimated and manually drawn but this method is prone to subjective over- or underestimation; thus more “objective” criteria, not operator-dependent, should be used, such as pixel count lying over a cut-off value (eg, >3 SD of the mean normal values).9 T1 area smaller than LGE area may be observed if imaging is performed too late after the acute event, in the case of poor slice co-localization (misregistration) or in the case of subendocardial infarction.
In the case of no-reflow with microvascular obstruction in the infarct core, a pseudo-normalization of T1 values is observed10,11 (Fig. 2A), and T1 is even more decreased in the case of hemorrhage (Fig. 2B), owing to methemoglobin accumulation.12
Myocarditis and Tako-tsubo syndrome, as well as recent infarction, include an area of edema leading to a focal area of increased T1 and T2 (see Table 2). In acute myocarditis (Fig. 3), this abnormal area is co-localized with regions of LGE13–15 because of associated cellular destruction; in contrast, no associated LGE is seen in Tako-tsubo7 as illustrated in Figure 4. Interestingly, beyond focal lesions, diffuse increase in myocardial T1 values, although of lower magnitude, is also observed in acute conditions as compared with healthy myocardium7,11,13–15 (cf: Table 2). This is particularly salient in cases of acute myocarditis, where the inflammatory process may be diffuse rather than discrete. In this setting, using ShMOLLI at 1.5 T, T1 mapping with a cut-off value of 990 ms offers optimal sensitivity (90%) and specificity (88%) as compared with T2-STIR and LGE imaging. Moreover, the T1 threshold approach is able to diagnose extra cases with small focal islands of myocardial injury, not detected by T2-STIR and LGE imaging.13,15
Myocardial inflammation related to several other diseases, not yet systematically studied up to now, may also provide focal or diffuse increase in T1 values. Systemic disorders that affect the heart, such as sarcoïdosis, lupus erythematosus, and systemic sclerosis, are known to induce tissue edema at the acute stage with elevated T2 (and T1) values.16 In these cases, T1 quantification may be useful to identify cardiac involvement (leading to therapeutic implications) and help assess a prognosis.17 T1 mapping also seems to have the potential to depict early rejection of transplanted hearts, as shown in Figure 5, which may obviate the need for more invasive endomyocardial biopsy, particularly in the case of primary graft dysfunction.18
Fibrosis
Fibrosis, which constitutes a common and final pathway in several cardiac diseases, may be discrete, focal (scar), or diffuse (uniform interstitial process).19–21 Expansion of the collagen matrix increases the volume of distribution (approximately from 20% to 30%), leading to combined pre-contrast T1 augmentation and greater gadolinium uptake (shorter post-contrast T1). Thus, focal lesions are assessable by both T1 mapping and LGE techniques. In contrast, in the case of diffuse, uniform T1 alteration, LGE is no longer able to depict abnormal patterns, since no relevant contrast is revealed between one region and another. In this case, T1 mapping circumvents the influence of windowing and reveals its strength, allowing a direct T1 quantification.
Focal replacement fibrosis (scar) in chronic MI
In the chronic stage of MI, edema resolves and is replaced by increased extracellular collagen (fibrous scar). The large area, initially identified with elevated T1 in the acute stage of infarction (edema), is replaced by a smaller area of scar tissue. This phenomenon may explain why both the magnitude and the extent of focal T1 increase are reduced when compared to the acute stage.9 However, even 6 months after infarction, some reports showed persistent edema (concomitant T2 increase), which could also account for T1 increase in chronic infarction.22 At 1.5 T, as seen in Figure 6, infarction demonstrated by LGE is seen incompletely on T1 maps and the rate of infarct scar identification was reported to be only 57%,23 particularly in cases of subendocardial lesion. In contrast, at 3 T, an experimental study in dogs demonstrated that T1 can accurately determine location, size, and transmurality of chronic MI, just as well as LGE.24 Similarly, a clinical study conducted in post-infarction patients with low mean ejection fraction (39%, synonymous of large infarction) showed that T1 mapping was able to detect chronic scar tissue caused by chronic MI with 95% sensitivity and 97% specificity, suggesting that accurate diagnosis could be reliably assessed even without LGE imaging,25 but this preliminary report needs to be confirmed.
Another added benefit of T1 mapping in old infarcts, illustrated in Figure 7, is a better view of lipomatous metaplasia, with noticeable T1 decrease in the fatty replacement area located within the infarct core.10,22
Diffuse interstitial fibrosis, cardiomyopathy
Myocardial fibrosis is composed of increased deposits of extracellular collagen associated with extracellular matrix expansion. Unlike replacement fibrosis, interstitial fibrosis may be reversible and is a target for treatment (eg, aldosterone).17 Histological markers of fibrosis have been shown to correlate with increased myocardial stiffness and impaired diastolic function, which are in turn associated with clinical vulnerability and adverse outcome.17 In recent years, a major interest in T1 mapping has focused on the significant correlation between the degree of fibrosis and increased T1 relaxation time.17,19–21 Reported correlations between histological collagen volume fraction determined from biopsy samples obtained during surgery for aortic valve replacement and T1 were good, with r = 0.6526 and r = 0.78.27
In patients with cardiomyopathies, heart failure, or aortic stenosis, four studies found significant myocardial T1 increase (presumably related to interstitial fibrosis) when compared to controls (cf: Table 2), but one other work (performed in heart failure patients) found a not significant +2% T1 increase.28 Puntmann et al reported the strongest difference with ≈+16% T1 increase in the septum. This T1 increase was correlated to left ventricular (LV) remodeling and systolic dysfunction in DCM patients and was correlated to LV mass index in HCM patients.29 Comparison of area under the curve (Receiver operating characteristic (ROC) analysis) showed that native T1 provided the best distinction between controls and patients with cardiomyopathy (as compared with post-contrast T1). Bull et al reported a +7% T1 augmentation in patients with aortic stenosis.26 T1 increase was less pronounced in the studies of Dass et al.30 (≈+3%, with changes being borderline if using ROI excluding LGE-positive regions) and of Lee et al.27 (+3.4% in patients with aortic stenosis). In fact, fibrosis involvement, visually perceivable as specific hyper-enhanced foci in HCM (Fig. 8) or quantified as a diffuse process on T1 quantification in DCM (Fig. 9), seems to appear inconstantly on T1 maps. The imperfect concordance between native T1 mapping and LGE imaging for detecting focal replacement fibrosis may be explained by the distinct significance of both imaging methods, since LGE (as well as post-contrast T1 mapping) reflects only extracellular space whereas native T1 mapping reflects a composite of both intra- and extracellular compartments.30 Imperfect identification of diffuse fibrosis in cardiomyopathies, with large inter-individual overlap between patient groups, probably results from the limited magnitude of T1 alterations in some fibrotic tissue at 1.5 T or even at 3 T, which may be better discriminated with improved sequences or at higher field strength.30
Several other diseases involving diffuse myocardial fibrosis and impaired diastolic function may reveal increased myocardial T1: diabetic cardiomyopathy, systemic or pulmonary hypertension, chronic renal disease, valvular heart disease, arrhythmogenic right ventricular cardiomyopathy, atrial fibrillation, and adult congenital heart disease.31 In patients with stable systemic lupus erythematosus, T1 increase (+9%), attributed to fibrosis rather than edema, was the best parameter to separate normal subjects from lupus patients.32 In patients with long standing systemic sclerosis (SSc) but without clinical sign of cardiac involvement, a +5% T1 increase was found as compared with controls. The volume fraction of T1 >990 ms (cut-off for detection of edema with ShMOLLI at 1.5 T) was 52% (vs 3% in controls). These T1 abnormalities were considered to represent a combination of low-grade chronic inflammation and diffuse myocardial fibrosis.33
Infiltrative, overload, and other cardiac diseases
Even before the advent of T1 mapping, systemic light-chain (AL) amyloidosis was recognized as a typical etiology of markedly elevated myocardial T1 values.34 In a series of 53 patients with biopsy-proven AL amyloidosis, Karamitsos et al demonstrated that T1 values correlated well with markers of systolic and diastolic dysfunction and were 19% higher than those in healthy subjects, with minimal overlap between groups.35 This was concordant with the presence of typical LGE pattern or with abnormal myocardial to blood pool signal suppression pattern indicative of diffuse myocardial infiltration (Fig. 10). In patients with transthyretin cardiac amyloidosis, T1 elevation was not found to be as high as in AL amyloidosis (+13% and +17%, respectively), but the area under the ROC curve was similar in both conditions (0.85 and 0.84, respectively).36 The great advantage of T1 mapping here is to be assessable even in patients with severe renal impairment precluding gadolinium chelates injection. Other foreseen advantages of T1 quantitation, as continuous metrics rather than a “binary” visual diagnosis provided by LGE, lie in the possible estimation of a patient’s prognosis and possible interesting tools for treatment monitoring.37
In contrast to previous causes of T1 increase, the London Heart Hospital group reported marked T1 lowering in two kinds of pathologies, both accessible in specific therapy: Ander-son–Fabry (Fig. 11) and iron overload diseases. Fabry disease is a rare but underdiagnosed lipid disorder with accumulation of intracellular glycosphingolipids. Mean septal T1 was reduced by 9% in these patients, and interestingly T1 reduction allowed for an efficient discrimination between Fabry disease and several other causes of left ventricular hypertrophy, with no overlap. T1 correlated inversely with wall thickness and was abnormal in 40% of subjects even without left ventricular hypertrophy (LVH).38 In the case of post-gadolinium contrast enhancement in the postero-lateral wall (a typical feature of this disease), T1 pseudo-normalization or augmentation was focally observed (effect of replacement fibrosis exceeding the fatty-related T1 decrease).
According to the same authors, cardiac iron overload (in transfusion-dependent patients, mostly including thalassemia major) seems to induce even greater T1 reduction. In these patients, T1 was reduced by −14% and T1 strongly correlated with T2* (r = 0.79). No patient with low T2* had normal T1, but 32% of patients with normal T2* (>20 ms) presented T1 lowering beyond 2 SD.39,40 Similar results and similar correlation between T1 and T2* (r = 0.83) were reported by Feng et al.41, indicating that T1 can be used reliably to assess myocardial iron and that T1 may help plan and monitor iron-chelating treatments.
Finally, aside from previously enumerated myocardial alterations, it is interesting to know that the order of magnitude of T1 values in adipose tissue (paracardiac fatty fringes, lipoma) and in pericardial effusion (Fig. 12) is, respectively, less than 500 and greater than 2000 ms (depending on chemical composition and shorter for protein-rich tran-sudate or abscesses as compared with transudate). Apart from ischemia and cardiomyopathies, T1 mapping reports are scarce for other pathological conditions such as cardiac masses, thrombi (Fig. 12), or tumors (Figs. 13 and 14), but case reports have been published for myxoma,42 calcified mitral pseudocyst,43 and lipomatous hypertrophy of the atrial septum.44
Conclusion
At present time, pre-contrast T1 mapping has not yet become the “non invasive biopsy” mentioned by Kramer.45 However, T1 mapping is already a useful tool for daily diagnostic in several conditions such as amyloidosis, Fabry, and iron overload diseases. Moreover, several reports suggest that in the future, it might become possible to rely on native T1 mapping instead of LGE imaging for accurate diagnosis of myocarditis and acute or chronic MI, particularly in patients with severe renal impairment precluding gadolinium contrast injection. Tissue characterization in subclinical cardiac injury involving diffuse fibrosis is another awaited clinical application, but overlap remains quite large with normal T1 values. T1 mapping is evolving rapidly and still requires methodological standardization. Objective quantification of abnormal myocardium with threshold-based T1 analysis (areas of injury) will probably help this highly reproducible and minimally operator-dependent technique to better define the prognosis and contribute to monitoring therapy in various myocardial diseases.
Acknowledgments
Authors thank the team of developers of the Siemens Quantitative Cardiac Parameter Mapping (WIP780): B Spottiswoode, A Greiser, C Glielmi, S Giri and R Kroeker and Mrs Ninon Teissier for English editing.
Footnotes
Author Contributions
Conceived and designed the experiment: PG, SE. Analyzed the data: PG, SE. Wrote the first draft: PG. Contributed to the writing: SE, MJ. Agree with results and conclusions: PO, EE, CR, AG. Developed structure and arguments: PG, SE, MJ. Made critical revisions: PG, SE, MJ. All authors reviewed and approved of the final manuscript.
ACADEMIC EDITOR: Thomas Vanhecke, Editor in Chief
FUNDING: Authors disclose no funding sources.
COMPETING INTERESTS: Authors disclose no potential conflicts of interest.
Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).
REFERENCES
- 1.Salerno M, Kramer CM. Advances in parametric mapping with CMR imaging. JACC Cardiovasc Imaging. 2013;6(7):806–22. doi: 10.1016/j.jcmg.2013.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6. doi: 10.1002/mrm.20110. [DOI] [PubMed] [Google Scholar]
- 3.Piechnik SK, Ferreira VM, Dall’Armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;19(12):69. doi: 10.1186/1532-429X-12-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Nagel E, Narula J. Evolution and revolution in CMR imaging. JACC Cardiovasc Imaging. 2013;6(7):837–8. doi: 10.1016/j.jcmg.2013.05.007. [DOI] [PubMed] [Google Scholar]
- 5.Higgins CB, Herfkens R, Lipton MJ, et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol. 1983;52(1):184–8. doi: 10.1016/0002-9149(83)90093-0. [DOI] [PubMed] [Google Scholar]
- 6.Goldfarb JW, Arnold S, Han J. Recent myocardial infarction: assessment with unenhanced T1-weighted MR imaging. Radiology. 2007;245(1):245–50. doi: 10.1148/radiol.2451061590. [DOI] [PubMed] [Google Scholar]
- 7.Ferreira VM, Piechnik SK, Dall’Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42. doi: 10.1186/1532-429X-14-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ugander M, Bagi PS, Oki AJ, et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging. 2012;5(6):596–603. doi: 10.1016/j.jcmg.2012.01.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Messroghli DR, Walters K, Plein S, et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007;58(1):34–40. doi: 10.1002/mrm.21272. [DOI] [PubMed] [Google Scholar]
- 10.Darach o h-Ici DO, Jeuthe S, Al-Wakeel N, et al. T1 mapping in ischaemic heart disease. Eur Heart J Cardiovasc Imaging. 2014;15(6):597–602. doi: 10.1093/ehjci/jeu024. [DOI] [PubMed] [Google Scholar]
- 11.Dall’Armellina E, Piechnik SK, Ferreira VM, et al. Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson. 2012;6(14):15. doi: 10.1186/1532-429X-14-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pedersen SF, Thrysøe SA, Robich MP, et al. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction. J Cardiovasc Magn Reson. 2012;14:59. doi: 10.1186/1532-429X-14-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ferreira VM, Piechnik SK, Dall’Armellina E, et al. T1 mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6(10):1048–58. doi: 10.1016/j.jcmg.2013.03.008. [DOI] [PubMed] [Google Scholar]
- 14.Luetkens JA, Doerner J, Thomas DK, et al. Acute myocarditis: multiparametric cardiac MR imaging. Radiology. 2014;132540 doi: 10.1148/radiol.14132540. [DOI] [PubMed] [Google Scholar]
- 15.Ferreira VM, Piechnik SK, Dall’Armellina E, et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson. 2014;16:36. doi: 10.1186/1532-429X-16-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mirakhur A, Anca N, Mikami Y, Merchant N. T2-weighted imaging of the heart – A pictorial review. Eur J Radiol. 2013;82(10):1755–62. doi: 10.1016/j.ejrad.2013.06.005. [DOI] [PubMed] [Google Scholar]
- 17.Burt JR, Zimmerman SL, Kamel IR, Halushka M, Bluemke DA. Myocardial T1 mapping: techniques and potential applications. Radiographics. 2014;34(2):377–95. doi: 10.1148/rg.342125121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Miller C, Naish J, Shaw S, et al. 118 Multiparametric cardiovascular magnetic resonance surveillance of acute cardiac allograft rejection and characterisation of transplantation-associated myocardial injury. Heart. 2014;100(suppl 3):A67–8. doi: 10.1186/s12968-014-0052-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903. doi: 10.1016/j.jacc.2010.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Jellis CL, Kwon DH. Myocardial T1 mapping: modalities and clinical applications. Cardiovasc Diagn Ther. 2014;4(2):126–37. doi: 10.3978/j.issn.2223-3652.2013.09.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hwang SH, Choi BW. Advanced cardiac MR imaging for myocardial characterization and quantification: T1 mapping. Korean Circ J. 2013;43(1):1–6. doi: 10.4070/kcj.2013.43.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Dall’Armellina E, Ferreira VM, Kharbanda RK, et al. Diagnostic value of pre-contrast T1 mapping in acute and chronic myocardial infarction. JACC Cardiovasc Imaging. 2013;6(6):739–42. doi: 10.1016/j.jcmg.2012.11.020. [DOI] [PubMed] [Google Scholar]
- 23.von Knobelsdorff F, Prothmann M, Dieringer MA, et al. Differentiation of acute and chronic myocardial infarction using T2-weighted imaging, late enhancement and T1 and T2 mapping - a pilot study at 3T. J Cardiovasc Magn Reson. 2014;16(suppl 1):222. [Google Scholar]
- 24.Kali A, Cokic I, Tang RL, et al. Determination of location, size, and transmurality of chronic myocardial infarction without exogenous contrast media by using cardiac magnetic resonance imaging at 3 T. Circ Cardiovasc Imaging. 2014;7(3):471–81. doi: 10.1161/CIRCIMAGING.113.001541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Okur A, Kantarcı M, Kızrak Y, et al. Quantitative evaluation of ischemic myocardial scar tissue by noncontrast T1 mapping using 3 Tesla MR scanner. Diagn Interv Radiol. 2014;20:407–13. doi: 10.5152/dir.13520.. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99(13):932–7. doi: 10.1136/heartjnl-2012-303052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Lee SP, Lee W, Lee JM, et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology. 2014 Sep 24;:141120. doi: 10.1148/radiol.14141120. (PubMed PMID: 25251584) [DOI] [PubMed] [Google Scholar]
- 28.Su MY, Lin LY, Tseng YH, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7(10):991–7. doi: 10.1016/j.jcmg.2014.04.022. [DOI] [PubMed] [Google Scholar]
- 29.Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475–84. doi: 10.1016/j.jcmg.2012.08.019. [DOI] [PubMed] [Google Scholar]
- 30.Dass S, Suttie JJ, Piechnik SK, et al. Myocardial tissue characterization using magnetic resonance non-contrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(6):726–33. doi: 10.1161/CIRCIMAGING.112.976738. [DOI] [PubMed] [Google Scholar]
- 31.Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging. 2010;3(6):727–34. doi: 10.1161/CIRCIMAGING.108.842096. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Puntmann VO, D’Cruz D, Smith Z, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6(2):295–301. doi: 10.1161/CIRCIMAGING.112.000151. [DOI] [PubMed] [Google Scholar]
- 33.Ntusi NA, Piechnik SK, Francis JM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis–a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson. 2014;16:21. doi: 10.1186/1532-429X-16-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hosch W, Bock M, Libicher M, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol. 2007;42(9):636–42. doi: 10.1097/RLI.0b013e318059e021. [DOI] [PubMed] [Google Scholar]
- 35.Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97. doi: 10.1016/j.jcmg.2012.11.013. [DOI] [PubMed] [Google Scholar]
- 36.Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–65. doi: 10.1016/j.jcmg.2013.10.008. [DOI] [PubMed] [Google Scholar]
- 37.Ruberg FL. T1 mapping in cardiac amyloidosis: can we get there from here? JACC Cardiovasc Imaging. 2013;6(4):498–500. doi: 10.1016/j.jcmg.2013.01.007. [DOI] [PubMed] [Google Scholar]
- 38.Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392–8. doi: 10.1161/CIRCIMAGING.112.000070. [DOI] [PubMed] [Google Scholar]
- 39.Sado DM, White SK, Piechnik SK, et al. Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease. J Cardiovasc Magn Reson. 2013;15(suppl 1):O71. [Google Scholar]
- 40.Sado DM, Maestrini V, Piechnik SK, et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging. 2014 Aug 8; doi: 10.1002/jmri.24727. PubMed PMID: 25104503. [DOI] [PubMed] [Google Scholar]
- 41.Feng Y, He T, Carpenter JP, et al. J Magn Reson Imaging; In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major. ; 2013. pp. 588–93. [DOI] [PubMed] [Google Scholar]
- 42.Kübler D, Gräfe M, Schnackenburg B, et al. T1 and T2 mapping for tissue characterization of cardiac myxoma. Int J Cardiol. 2013;169(1):e17–20. doi: 10.1016/j.ijcard.2013.08.116. [DOI] [PubMed] [Google Scholar]
- 43.Reiter U, Reiter G, Asslaber M, et al. Characterization of a calcified intra-cardiac pseudocyst of the mitral valve by magnetic resonance imaging including T1 and T2 mapping. BMC Cardiovasc Disord. 2014;14:11. doi: 10.1186/1471-2261-14-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ferreira VM, Holloway CJ, Piechnik SK, Karamitsos TD, Neubauer S. Is it really fat? Ask a T1-map. Eur Heart J Cardiovasc Imaging. 2013;14(11):1060. doi: 10.1093/ehjci/jet095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kramer CM, Chandrashekhar Y, Narula J. T1 mapping by CMR in cardiomyopathy: a noninvasive myocardial biopsy? JACC Cardiovasc Imaging. 2013;6(4):532–44. doi: 10.1016/j.jcmg.2013.02.002. [DOI] [PubMed] [Google Scholar]